Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivastigmine Twice-Weekly Patch vs Exelon Daily Patch
NCT05853341Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Area Under the Curve from 96 to 264 hours, Maximum Plasma Concentration from 96 to 264 hours and 1 more. Started May 2023; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05853341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05853341.